SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Adamis Pharmaceuticals Corp (DMKPQ) (CIK 0000887247) — Jul 28, 2023

Adamis Pharmaceuticals Corp (DMKPQ) (CIK 0000887247)
Date: July 28, 2023 · CIK: 0000887247 · Accession: 0001387131-23-009026

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-273233

Date
July 28, 2023
Author
Co-President
Form
CORRESP
Company
Adamis Pharmaceuticals Corp (DMKPQ) (CIK 0000887247)

Letter

Re: Adamis Pharmaceuticals Corporation

July 28, 2023

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Registration Statement on Form S-1

File No. 333-273233

Request for Acceleration of Effective Date

Ladies and Gentlemen:

Reference is made to our letter, filed as correspondence via EDGAR on July 26, 2023, in which we, as placement agent for the above-referenced offering, joined in the request of Adamis Pharmaceuticals Corporation (the “Company”) for acceleration of the effective date of the above-referenced Registration Statement for July 28, 2023, at 9:00 a.m. Eastern Time. The Company is no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.

Very truly yours,
MAXIM GROUP LLC

Show Raw Text
CORRESP
1
filename1.htm

July 28, 2023

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

    Re:
    Adamis Pharmaceuticals Corporation

    Registration Statement on Form S-1

    File No. 333-273233

    Request for Acceleration of Effective Date

Ladies and Gentlemen:

Reference is made to our letter, filed as correspondence
via EDGAR on July 26, 2023, in which we, as placement agent for the above-referenced offering, joined in the request of Adamis Pharmaceuticals
Corporation (the “Company”) for acceleration of the effective date of the above-referenced Registration Statement for
July 28, 2023, at 9:00 a.m. Eastern Time. The Company is no longer requesting that such Registration Statement be declared effective at
this time and we hereby formally withdraw our request for acceleration of the effective date.

    Very truly yours,

    MAXIM GROUP LLC

    By:
    /s/ Clifford A. Teller

    Name:
    Clifford A. Teller

    Title:
    Co-President